J Stebbing1, A Dalgleish2, A Gifford-Moore3, A Martin3, C Gleeson4, G Wilson4, L R Brunet4, J Grange4, S Mudan5. 1. Department of Oncology, Imperial College and Imperial College Healthcare NHS Trust, London. Electronic address: j.stebbing@imperial.ac.uk. 2. Department of Oncology, St George's University of London, London. 3. HCA International, London. 4. Immodulon Therapeutics Limited, London. 5. Immodulon Therapeutics Limited, London; Department of Surgery, St George's University of London, London, UK.
Abstract
BACKGROUND: IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma. PATIENTS AND METHODS: An intra-patient placebo-controlled study evaluated the safety and tolerability of three doses, namely, 0.1 (1 mg/ml), 0.5 (5 mg/ml) and 1.0 mg (10 mg/ml) of IMM-101 in stage III or IV melanoma. Each dose was administered in ascending order to one of the three cohorts. RESULTS: Based on observations from patients administered the 0.1-mg dose, it was considered appropriate to proceed with dosing the patients in the 0.5-mg dose cohort and then the 1.0-mg cohort (n = 6 per cohort). Treatment-emergent adverse events that would be considered typical of a post-vaccination state (including joint pains/aches, headaches and influenza-like symptoms) occurred at all dose levels, along with injection site reactions. These were mainly mild in intensity, resolved in a matter of days and responded well to supportive care. During post-study follow-up, two clinical responses (15%) were observed in patients with stage IV disease. CONCLUSION: IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer.
BACKGROUND: IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma. PATIENTS AND METHODS: An intra-patient placebo-controlled study evaluated the safety and tolerability of three doses, namely, 0.1 (1 mg/ml), 0.5 (5 mg/ml) and 1.0 mg (10 mg/ml) of IMM-101 in stage III or IV melanoma. Each dose was administered in ascending order to one of the three cohorts. RESULTS: Based on observations from patients administered the 0.1-mg dose, it was considered appropriate to proceed with dosing the patients in the 0.5-mg dose cohort and then the 1.0-mg cohort (n = 6 per cohort). Treatment-emergent adverse events that would be considered typical of a post-vaccination state (including joint pains/aches, headaches and influenza-like symptoms) occurred at all dose levels, along with injection site reactions. These were mainly mild in intensity, resolved in a matter of days and responded well to supportive care. During post-study follow-up, two clinical responses (15%) were observed in patients with stage IV disease. CONCLUSION: IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer.
Authors: Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief Journal: Nat Rev Cancer Date: 2016-03-11 Impact factor: 60.716
Authors: Frank M Speetjens; Marij J P Welters; Marije Slingerland; Mariette I E van Poelgeest; Peggy J de Vos van Steenwijk; Inge Roozen; Sanne Boekestijn; Nikki M Loof; Gijs G Zom; A Rob P M Valentijn; Willem-Jan Krebber; Nico J Meeuwenoord; Catharina A H Janssen; Cornelis J M Melief; Gijs A van der Marel; Dmitri V Filippov; Sjoerd H van der Burg; Hans Gelderblom; Ferry Ossendorp Journal: J Immunother Cancer Date: 2022-10 Impact factor: 12.469
Authors: Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti Journal: Front Oncol Date: 2014-11-28 Impact factor: 6.244